These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6627748)

  • 1. The effect of ketanserin in essential hypertension.
    Anderson A; Morgan T; Dumpys R
    Clin Exp Pharmacol Physiol; 1983; 10(3):331-3. PubMed ID: 6627748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of preeclamptic hypertension by ketanserin, a new serotonin receptor antagonist.
    Weiner CP; Socol ML; Vaisrub N
    Am J Obstet Gynecol; 1984 Jul; 149(5):496-500. PubMed ID: 6377898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension.
    Hedner T; Persson B; Berglund G
    Br J Clin Pharmacol; 1983 Aug; 16(2):121-5. PubMed ID: 6615685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive properties of ketanserin in combination with beta-adrenergic blocking agents.
    Hedner T; Persson B
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S161-3. PubMed ID: 2412042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative and long-term evaluation of ketanserin in the treatment of essential hypertension.
    Hedner T; Persson B; Berglund G
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S148-53. PubMed ID: 2412038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ketanserin: a possible tool for studying the role of serotonin in hypertension.
    Woittiez AJ; Wenting GJ; Man in't Veld AJ; Boomsma F; Schalekamp MA
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S130-6. PubMed ID: 2412035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with ketanserin, a serotonin (S2) antagonist, in longterm treatment of essential hypertension.
    Hedner T; Persson B; Berglund G
    Clin Exp Hypertens A; 1984; 6(3):743-51. PubMed ID: 6373066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of arterial hypertension with ketanserin in mono- and combination therapy.
    Pettersson A; Persson B; Berglund G; Hedner T
    Clin Pharmacol Ther; 1985 Aug; 38(2):188-94. PubMed ID: 2861930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist.
    Andrén L; Svensson A; Dahlöf B; Eggertsen R; Hansson L
    Acta Med Scand; 1983; 214(2):125-30. PubMed ID: 6353879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute effects of antagonist of S2-receptors.
    Petkovská N; Brimichová G; Tison P; Dzúrik R
    Czech Med; 1984; 7(4):210-4. PubMed ID: 6084584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ketanserin in essential hypertension: a double-blind, placebo-controlled study.
    Cameron HA; Ramsay LE
    Postgrad Med J; 1985 Jul; 61(717):583-6. PubMed ID: 3161013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular effects of ketanserin, a new antiserotonergic agent in the treatment of arterial hypertension.
    Ferrara LA; Fasano ML; Soro S; Rubba P; Iannuzzi A
    J Clin Pharmacol; 1985 Apr; 25(3):187-92. PubMed ID: 3158674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study with the competitive 5-HT2-serotonergic antagonist ketanserin.
    Ferrara LA; Fasano ML; Rubba P; Soro S; Marotta G; Mancini M
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S159-60. PubMed ID: 2412041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moderate essential hypertension control: a double-blind crossover study between a serotonin antagonist and a post-synaptic alpha-blocker.
    Rosenthal J; Koehle W; Gruebel B; Fisher R
    J Hypertens Suppl; 1986 Apr; 4(1):S85-7. PubMed ID: 2871145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical studies with ketanserin in hypertension.
    Waal-Manning HJ; Brown SA; Spears GF; Simpson FO
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S154-8. PubMed ID: 2412040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood pressure, 5-OH indoleacetic acid, and vanilmandelic acid excretion and blood platelet aggregation in hypertensive patients treated with ketanserin.
    Dzúrik R; Fetkovská N; Brimichová G; Tison P
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S29-31. PubMed ID: 2412052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is prevention of hypertension after open heart surgery possible by blocking 5HT2-receptors with ketanserin?
    van den Broeke JJ; Karliczek GF; Brenken U; Schokkenbroek R; Homan van der Heide JN
    Acta Anaesthesiol Belg; 1982; 33(2):115-20. PubMed ID: 6981913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ketanserin in primary aldosteronism.
    Mantero F; Rocco S; Opocher G; Armanini D; Boscaro M; D'Agostino D
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S172-5. PubMed ID: 2412045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ketanserin in the acute management of severe hypertension.
    Murphy BF; Whitworth JA; Kincaid-Smith P
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S168-71. PubMed ID: 2412044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodynamic response to chronic ketanserin treatment in essential hypertension.
    Fagard R; Fiocchi R; Lijnen P; Staessen J; Amery A
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S128-9. PubMed ID: 2412034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.